Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

References

Page 1

	Year	Citations
Global cancer statistics Ahmedin Jemal, Freddie Bray CA A Cancer Journal for Clinicians	2011	55K
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) E. Eisenhauer, P. Therasse, Jan Bogaerts, European Journal of Cancer Surgical OncologyRecist GuidelineMedicineCancer ManagementSolid Tumours	2008	28.6K
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, New England Journal of Medicine	2004	11.4K
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, New England Journal of Medicine	2016	9.8K
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee, Science	2004	9.4K
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer H. Borghaei, L. Paz-Ares, Leora Horn, New England Journal of Medicine	2015	9.3K
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer Julie R. Brahmer, Karen L. Reckamp, Paul Baas, New England Journal of Medicine	2015	8.4K
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, New England Journal of Medicine	2009	8.2K
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, Science	2015	7.8K
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer Jennifer S. Temel, Joseph A. Greer, Alona Muzikansky, New England Journal of Medicine	2010	7.2K

Page 1